TRIVOGO 2 TAB 10 S

About

TRIVOGO 2 TAB is a triple-combination oral antidiabetic medication designed for the comprehensive management of type 2 diabetes mellitus. It typically contains Voglibose, an alpha-glucosidase inhibitor that delays carbohydrate absorption; Metformin, a biguanide that reduces hepatic glucose production and improves insulin sensitivity; and Glimepiride, a sulfonylurea that stimulates insulin secretion from pancreatic beta cells.

This multi-pronged approach targets different aspects of glucose metabolism, providing robust glycemic control, particularly in patients whose blood sugar levels are not adequately managed by dual therapy or other single agents. The combination aims to reduce both fasting and post-meal glucose excursions, thereby lowering HbA1c and mitigating the risk of long-term diabetic complications.

Uses

• Management of type 2 diabetes mellitus.
• To improve glycemic control in adults.
• When dual therapy is insufficient.
• As an adjunct to diet and exercise.

Directions For Use

Take this medication orally with meals, as directed by your physician. Swallow the tablet whole with water.

Benefits

• Provides comprehensive glycemic control.
• Significantly lowers HbA1c levels.
• Targets multiple pathways of glucose metabolism.
• Reduces both fasting and post-meal blood sugar.
• Helps prevent long-term diabetic complications.
• Offers a potent option for difficult-to-control diabetes.

Side Effects

• Hypoglycemia (low blood sugar)
• Nausea
• Diarrhea
• Abdominal pain
• Flatulence
• Headache
• Dizziness
• Metallic taste in mouth
• Skin rash
• Weight gain (due to Glimepiride)
• Lactic acidosis (rare but serious)
• Blood dyscrasias (rare, e.g., leukopenia)

Safety Measures

• Alcohol - Avoid excessive alcohol consumption as it can increase the risk of hypoglycemia (with Glimepiride), lactic acidosis (with Metformin), and disulfiram-like reactions.
• Pregnancy - Contraindicated during pregnancy due to potential harm to the fetus, especially with sulfonylureas.
• Breastfeeding - Contraindicated during breastfeeding as components may pass into breast milk and cause hypoglycemia in the infant.
• Liver - Contraindicated in severe hepatic impairment due to increased risk of hypoglycemia (with Glimepiride) and lactic acidosis (with Metformin).
• Kidney - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²) due to Metformin accumulation and increased lactic acidosis risk. Glimepiride also requires caution.
• Lung - No specific contraindications related to lung conditions, but severe respiratory failure can increase lactic acidosis risk.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.